You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Home Monitoring of Metabolic Disorders

    SBC: SEQUITUR HEALTH CORP            Topic: NICHD

    PROJECT SUMMARY This proposal is submitted in direct response to NOT-HD-22-009 Notice of Special Interest (NOSI): Innovative Technologies to Improve Assessments, Interventions, and Outcomes for Individuals with Intellectual and Developmental Disabilities [IDD] (R43/R44). Persons of all ages with certain metabolic disorders are at-risk for metabolic crises when a certain metabolite accumulates, whi ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Dodecafluoropentane emulsion (DDFPe), NanO2™ as Cerebroprotectant in Ischemic Stroke

    SBC: NUVOX PHARMA, L.L.C.            Topic: NINDS

    ABSTRACT / PROJECT SUMMARY Stroke affects more than 795,000 patients per year in the US and kills approximately 40,000. Long-term medical care expense for stroke in the US, costs over $34B per year. Large vessel occlusion (LVO) stroke accounts for almost 40% of ischemic strokes but causes 95% of mortality and 62% of long-term dependence. Mechanical thrombectomy (MT), or a combination of MT and tPA ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Enabling Toxoplasma gondii Kinome Directed Drug Discovery

    SBC: LUCEOME BIOTECHNOLOGIES, L.L.C.            Topic: NIAID

    Project Summary Toxoplasma gondii (T.gondii), the causative agent for toxoplasmosis, invades host cells through ingestion of uncooked infected meat or contaminated water. T.gondii infects 30% of the world’s population and the current cost of the disease in US itself is estimated to be $3B and rising. Current treatment regimen is effective only against acute infection and has severe side effects. ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health

    SBC: NEUTHERAPEUTICS, LLC            Topic: NIA

    PROJECT SUMMARY/ABSTRACT Women are at greater life-time risk for Alzheimer’s disease (AD). One potential factor contributing to greater life-time risk of AD is the midlife menopausal endocrine aging transition when multiple AD risk conditions can emerge and which are consistent with prodromal / preclinical features of the disease. While estrogen or hormone therapy administered when menopausal wo ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  5. Development of SP-A Derived Peptidomimetics for the Treatment of Asthma- Phase II

    SBC: RaeSedo, LLC            Topic: NHLBI

    Current treatments for asthma, while reducing exacerbations in a subset of patients by focusing on airway inflammation, do not eliminate them. Asthma exacerbations are a significant cause of morbidity and mortality in asthma as they can lead to airway injury, lung function decline and death. Exacerbations in more severe asthmatics are of particular concern, as health care costs and lost productivi ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Cutaneous Phosphorylated Alpha-Synuclein for Detection of Prodromal Synucleinopathies

    SBC: CND LIFE SCIENCES, INC.            Topic: 105

    PROJECT SUMMARY A group of devastating diseases, collectively termed synucleinopathies, affect over 2 million people in the U.S., carry significant morbidity, high mortality and enormous associated health care costs. Synucleinopathies are characterized by the abnormal deposition of a misfolded protein, phosphorylated α−synuclein (P-SYN), within the central and peripheral nervous systems. Synucl ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Preventing Neurovascular Matrix Degradation and Hemorrhage in Acute Ischemic Stroke

    SBC: TRANSLATIONAL SCIENCES INC            Topic: NHLBI

    Each year ~12 million people each year suffer from an ischemic stroke. Millions are left disabled and ~3 million die. Treatment with recombinant tissue plasminogen activator (r-tPA) treatment significantly reduces patient disability. However, r-tPA therapy does not reduce mortality and it causes some form of brain hemorrhage in up to 30% of patients. In selected r-tPA-treated patients with large v ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Novel Sensor Integrated Proteome on Chip (SPOC) platform for evaluating kinetic parameters of protein interactions in high throughput

    SBC: SPOC PROTEOMICS INC.            Topic: 100

    Abstract A critical bottleneck in the field of proteomics is the inability to simultaneously and cost-effectively evaluate thousands of functional protein interactions at once to obtain kinetic data. Although conventional in-situ protein microarray technology is well developed, it uses fluorescent dye based detection that provides only qualitative or semi-quantitative information. There is current ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a chemical reaction sensor array platform for label-free, real-time kinetic analysis of enzyme-substrate reactions to enable high-throughput drug discovery

    SBC: SPOC PROTEOMICS INC.            Topic: NCATS

    Project SummaryGlobal expenditures by pharmaceutical companies for research and development continue to increase each year with a current estimate of $1B USD and upwards of 15 years to develop a new drug. Drug discovery efforts are critical to the downstream success of candidate selection and relies heavily on high-throughput screening (HTS) to identify viable leads. Current methods for HTS drug d ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  10. Sedationless Multi-View High-Resolution Endoscopy

    SBC: Omniscient Imaging, Inc.            Topic: 102

    Abstract An upper endoscope is designed for the endoscopic evaluation of the esophagus, stomach and duodenum, however, of the six-million upper endoscopies performed annually in the US, about half are for the disorders of the esophagus alone, where it can be argued that a full endoscopy of these three organs is not necessary in many, particularly since the procedure requires sedation with its asso ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government